Dezima Pharma

Develops drugs to treat dyslipidemic patients suffering from cardiovascular diseases.

Launch date

2012–2016

Market cap

Enterprise valuation

CAD409m (Public information from Mar 2017)

Company register number 55971946

Naarden North Holland (HQ)

Revenues, earnings & profits over time

EUR	2016
Profit	(86.6m)

Date	Investors	Amount	Round
-	TPG BioGeneration Ventures (BGV)	N/A	-
Feb 2013	N/A	€14.2m	Early VC
Sep 2015	Amgen	$300m Valuation: $300m	Acquisition
Total Funding		CAD21.3m

exited

Financials